Additional file 2 of Extrapolating from trials to clinic: a predictive model defining the boundaries of benefit for multiple sclerosis therapies in real-world populations based on systematic review

Additional file 2: Table s1. Raw data (SAS input). Tables s2-s12. SAS analyses exports. Table s2. Predicting mean age of recruited population from trial Inclusion/Exclusion criteria. Table s3. Effect of publication year on ARR of placebo arms. Table s4. Effect of publication year on A-CDP of placebo arms. Table s5. Effect of age on baseline CEL#. Table s6. Effect of age on baseline ARR. Table s7. Effect of age on the on-trial measured ARR in the placebo arms. Table s8. Predicting ARR from CEL#. Table s9. Predicting A-CDP in the placebo arms. Table s10. Predicting A-CDP in the treatment arms of placebo-controlled trials. Table s11. Predicting treatment efficacy (A-CDP%D). Table s12. Simple correlations of baseline characteristics with efficacy outcomes. Table s13. Independent validation cohort raw data. Table s14. ICD-based 2001-2021 age-related mortality data. Table s15. ICDbased 2001-2021 age-related infections mortality. Table s16. ICD-based 2001-2021 age-related cancer mortality.